Enhancing immunity to malaria in young children with effective chemoprevention
Enhancing immunity to malaria in young children with effective chemoprevention
批准号:
10449289
负责人:
Prasanna Jagannathan
金额:
$124.07万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-12 至 2026-06-30
关键词:
1 year old2 year old4 year oldAddressAffectAfricaAfricanAntigensAntimalarialsAreaAutomobile DrivingBiological AssayBirthBloodCellsCessation of lifeChemopreventionChildChildhoodClinical TrialsDataDevelopmentDirectly Observed TherapyEnrollmentFalciparum MalariaFundingGene ExpressionGuidelinesHealth BenefitImmuneImmune responseImmunityImmunologyIncidenceInfantInfant HealthInfectionInflammatoryInterleukin-10InterventionInvestigationLifeMalariaMalaria VaccinesMalaria preventionMorbidity - disease rateMothersOutcomeParentsPharmaceutical PreparationsPoliciesPopulationPregnancyPregnant WomenPreventionPreventive treatmentPyrimethamine-SulfadoxineRandomizedRandomized Controlled TrialsRegimenResearch DesignRiskSerologySystemTNF geneTestingTimeToll-like receptorsUgandaVaccine AntigenViral AntigensWomanadaptive immune responsearmbasecohortcritical developmental periodearly childhoodfollow-upimmunopathologyimmunoregulationimprovedin uteroinfancyinnovationmalaria infectionmalaria transmissionmortalitymultidisciplinaryprenatal exposurepreventprimary outcomeprotein expressionresponsestandard of care
中文摘要
项目摘要/摘要
疟疾继续导致每年40多万人死亡,主要是非洲儿童。有效
对疟疾的免疫力在流行人群中形成,但只有在多次反复感染之后才会产生。间歇性
孕期预防治疗(IPTp)和儿童预防治疗(IPTC)已成为减少
儿童发病率和死亡率,但令人担忧的是,在生命早期预防疟疾暴露将推迟
抗疟疾免疫的发展。然而,我们小组的数据表明,干预措施
在这一关键时期选择性地阻断疟疾感染的血液阶段实际上可能会增强抗疟疾作用
豁免权。在这项提案中,我们将检验预防血液期疟疾抗原暴露的假设
在子宫和患有IPT的幼儿中,通过限制疟疾诱导的免疫增强对疟疾的保护性免疫
免疫调节机制。为了验证这一假设,我们将利用一个独特的机会
对东部地区不同IPTp方案的资助临床试验的母亲所生的孩子进行研究
乌干达的疟疾传播率非常高。在这项家长研究中,2757名孕妇将被
随机接受IPTp与磺胺多辛-乙胺(SP,低效,目前的标准
CARE),高效药物双氢青蒿素-哌喹(DP),或两种SP DP。我们将利用这一点
一项父母研究,招募了924名儿童的出生队列,这些儿童在出生时将被随机分配到不接受IPTC,IPTC
每月DP至1岁,或IPTC每月DP至2岁。儿童将被跟踪到4岁以下
几年前。这一独特的研究设计将使我们能够确定是否有效地预防血液期
孕期和婴儿期使用以DP为基础的IPT接触疟疾对幼儿有持久的好处
与目前的护理标准相比。我们的具体目标将是(1)比较疟疾的发病率
在母亲随机接受每月IPTp治疗的儿童中,从出生到4岁,
DP,或DP SP,(2)比较2至4岁儿童的疟疾发病率
随机在婴儿期不接受IPTC,第一年每月接受DP,或前两年每月接受DP
以及(3)确定有效的IPT预防疟疾是否会导致较低的监管
以及增强的先天和获得性免疫反应。通过确定是否有效的预防
孕期和婴儿期疟疾的IPT对婴儿健康有长期、持久的益处,这项研究
可以为政策指导方针提供关键信息,包括将IPT的使用扩大到疟疾的环境
传播是一年四季的。这些研究还将显著提高我们对如何预防
生命早期的疟疾影响婴儿免疫发育和获得抗疟疾免疫。
英文摘要
PROJECT SUMMARY/ABSTRACT
Malaria continues to result in more than 400,000 deaths annually, mainly in young African children. Effective
immunity to malaria develops in endemic populations, but only after many repeated infections. Intermittent
preventive treatment in pregnancy (IPTp) and childhood (IPTc) have emerged as strategies to decrease
childhood morbidity and mortality, but there is concern that preventing malaria exposure early in life will delay
the development of antimalarial immunity. However, data from our group suggests that interventions that
selectively block the blood stage of malaria infection during this critical time may actually enhance antimalarial
immunity. In this proposal, we will test the hypothesis that preventing blood-stage malaria antigenic exposure
in utero and in young children with IPT enhances protective immunity to malaria by limiting malaria-induced
immunoregulatory mechanisms. To test this hypothesis, we will take advantage of a unique opportunity to
study children born to mothers enrolled in a funded clinical trial of different IPTp regimens in an area of eastern
Uganda with very high malaria transmission intensity. In this parent study, 2757 pregnant women will be
randomized to receive IPTp with sulfadoxine-pyrimethamine (SP, the poorly effective, current standard of
care), the highly effective drug dihydroartemisinin-piperaquine (DP), or both SP+DP. We will leverage this
parent study to enroll a birth cohort of 924 children who will be randomized at birth to receive no IPTc, IPTc
with monthly DP to 1 year of age, or IPTc with monthly DP to 2 years of age. Children will be followed up to 4
years of age. This unique study design will allow us to determine whether effective prevention of blood-stage
malaria exposure with DP-based IPT both in pregnancy and in infancy has lasting benefits for young children
compared with the current standard of care. Our specific aims will be (1) to compare the incidence of malaria
from birth up to 4 years of age among children born to mothers randomized to receive monthly IPTp with SP,
DP, or DP+SP, (2) To compare the incidence of malaria from 2 up to 4 years of age among children
randomized to receive no IPTc in infancy, monthly DP for the first year of life, or monthly DP for the first two
years of life, and (3) To determine whether prevention of malaria with effective IPT leads to lower regulatory
responses and enhanced innate and adaptive immune responses. By determining whether effective prevention
of malaria with IPT during pregnancy and infancy leads to long-term, lasting benefits on infant health, this study
could critically inform policy guidelines, including extending the use of IPT to settings where malaria
transmission is year-round. These studies will also significantly improve our understanding of how preventing
malaria early in life affects infant immune development and the acquisition of antimalarial immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancing immunity to malaria in young children with effective chemoprevention
-
批准号:10263680
-
项目类别:
-
资助金额:$128.3万
-
财政年份:2021
-
负责人:Prasanna Jagannathan
-
依托单位:
Enhancing immunity to malaria in young children with effective chemoprevention
-
批准号:10683090
-
项目类别:
-
资助金额:$125.21万
-
财政年份:2021
-
负责人:Prasanna Jagannathan
-
依托单位:
Immunologic consequences of highly effective antimalarial chemoprevention
-
批准号:8650787
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2012
-
负责人:Prasanna Jagannathan
-
依托单位:
Immunologic consequences of highly effective antimalarial chemoprevention
-
批准号:8463455
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2012
-
负责人:Prasanna Jagannathan
-
依托单位:
Immunologic consequences of highly effective antimalarial chemoprevention
-
批准号:8353165
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2012
-
负责人:Prasanna Jagannathan
-
依托单位:
海外基金